Pharma Marketing Network

Welcome to the July 7, 2017, issue of Pharma Industry News Update (aka PinUp). We talked about 'influencer marketing' in a previous issue of PinUIp. That newly-minted 'buzzword' generally applies to using real patients to influence other patients. But the pharmaceutical industry has long used physicians to influence other physicians. As we see in this issue of PinUp, physicians who have received payments from drug companies are also influencing FDA drug panels.

Back in March, 2017, President Trump "called on the Food and Drug Administration to speed the approval of drugs to treat life-threatening diseases, deriding...

Welcome to the June 23, 2017, issue of Pharma Industry News Update (aka PinUp). The relationship between the pharmaceutical industry and patients is often a riddle, wrapped in a mystery, inside an enigma. This is especially true of how the industry funds and benefits from so-called 'patient advocacy groups and organized 'patient activists.'

Recently, I was sorry to see that the eHealth Code of Ethics, which I helped create back in 2000, was not included in the...

Welcome to the June 27, 2017, issue of Pharma Industry News Update (aka PinUp). Can we trust the pharmaceutical industry to present unbiased information to physicians? In some cases, physicians may be overwhelmed by positive data without being adequately informed about the context of that data; e.g., disclosure of clinical trial endpoints. Patients too may not have access to all the information they need.

Welcome to the June 23, 2017, issue of Pharma Industry News Update (aka PinUp). This issue of PinUp focuses on the credibility of health information on the Web in general and specifically communications from pharma companies via blogs and press releases.

Welcome to the June 20, 2017, issue of Pharma Industry News Update (aka PinUp). Drug industry direct-to-consumer (DTC) ads - including non-branded disease awareness ads - have long been criticized as being uncreative. Ad agencies that produce these ads often cite FDA regulations as the cause. These days, FDA may be more accommodating by allowing ad creatives to do without some of the side effect information. But first, they must study the issue!

Welcome to the June 16, 2017, issue of Pharma Industry News Update (aka PinUp). You have to give kudos to the good doctors and policy makers of the American Medical Association for trying over the course of many to ban or in some way curtail direct-to-consumer drug ads by pharmaceutical companies. The latest effort focuses on drug price transparency in ads. Will it succeed where the other efforts have failed?

Welcome to the June 13, 2017, issue of Pharma Industry News Update (aka PinUp). PhRMA - the drug industry's trade association - defends high drug prices as necessary to fund the development of new and innovative medicines. The message, however, may be falling on deaf consumer ears.

In December 2008, the PhRMA Board of Directors unanimously adopted measures to enhance the PhRMA Guiding Principles on Direct to Consumer Advertisements about PrescriptionMedicines. The...